TickerSpark Feed

drug manufacturers general

Everything tagged "drug manufacturers general" across research, earnings, and macro.

3 articles

Amgen (AMGN): Growth Broadens Beyond Patent Cliffs

Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.

May 1, 2026·21 min read

Healthcare Drug Manufacturers - General Biotech

Research ReportLLY

Eli Lilly (LLY): Incretin Growth Still Drives the Story

Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.

Apr 30, 2026·27 min read

Healthcare Drug Manufacturers - General Growth

Research ReportGSK

GSK (GSK): Specialty Medicines Drive a Re-Rating

GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.

Apr 29, 2026·21 min read

Healthcare Drug Manufacturers - General Healthcare

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator